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Dear Subscriber,
On the following pages you will find four documents:
1) A Patient Handout on the several “dangerous” drugs that have been highlighted in the
Toronto Star and U.S. news since the FDA official told Congress about them. This Patient
Handout covers Celebrex, Crestor (the statins), and several others.
2) A Patient Handout on JUST the COX-2 inhibitors and naproxen for you to use if patients are
asking about only these.
3) A Health Canada Advisory on COX-2 inhibitors.
4) Professional Information for you covering all of these drugs.
You may use your choice of either (or both) of the Patient Handouts to suit your needs. Active
subscribers have our permission to reproduce copies of the Patient Handouts for you to hand to
your own patients. (Mass reproduction or electronic forwarding or dissemination is not
authorized.)
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Patient Handout

“Dangerous Drugs” in the News
The removal from the market of the painkillers Vioxx (rofecoxib) and Bextra (valdecoxib),
because of the possibility that they cause heart attacks and strokes, has led people to question the
safety of other medicines. A recent report in the Toronto Star newspaper highlighted medicines
or medicine groups that the writers felt were unsafe. Additionally, there is some current news
about Celebrex, which is also a painkiller like Vioxx and Bextra. You may have heard about
these as well. Here is some information to help you understand these medicines.
Cholesterol-lowering medicines-“the statins”
The cholesterol lowering medicines known as “the statins” (examples include Lipitor,
Crestor, Zocor, and others) lower levels of bad cholesterol. While they are very effective at
lowering cholesterol, they can also rarely cause side effects. Some of the most severe side
effects include liver damage and breakdown of muscles which can cause muscle pain and kidney
damage. For this reason, your health care professional will order blood tests to check your liver.
Also, you should call your health care professional if you start to get muscle pain or weakness,
unusual nausea, abdominal pain, fatigue, dark urine, pain when urinating, pale stools, or yellowlooking eyes or skin.
Weight-loss medicines – Meridia (sibutramine) and Xenical (orlistat)
You may have heard about the weight loss medicines called Meridia and Xenical.
Meridia creates a feeling of fullness, but can also cause high blood pressure and increase the
heart rate, which can lead to stroke or heart attack. But those needing to take weight loss
products like Meridia may already have blood pressure problems. If you take Meridia, you
should have your blood pressure and heart rate checked regularly. Also, people who have had
heart problems or strokes in the past should not use Meridia.
Xenical decreases the amount of fat that is absorbed into the body. But that effect can also
cause your stool to be oily and loose. Other side effects are stomach cramping, diarrhea,
inflammation of the pancreas, and vitamin deficiencies. If you take Xenical, you should divide
your daily fat intake evenly over your three main meals and take a multivitamin that contains
vitamins D, E, K, and beta-carotene. This multivitamin should be taken at least two hours before
or after taking your Xenical.
Zyban (bupropion)
Zyban is a non-nicotine medicine to help people stop smoking. Zyban reduces the nicotine
withdrawal symptoms and the urge to smoke. It is more effective when people also go to a
patient support program. However, there is concern about a number of side effects. Rarely,
patients who are taking Zyban have had heart attacks. But, it is hard to tell if they had a heart
attack because they have heart disease from years of smoking or if the heart attack happened
because of the Zyban. Other side effects include thoughts of suicide or suicide attempts and
seizures.
If you have had a seizure disorder, eating disorder such as bulimia or anorexia nervosa, or are
stopping the use of alcohol or sedatives, you should not take Zyban since these conditions may
increase the chance of seizures. Also, you should not take more than 150 mg twice a day. With
your families help, you should watch for depression or thoughts of suicide or feelings of anxiety,
irritability, hostility, severe restlessness, overly excited behavior, or not being able to sleep.
These symptoms should be reported to your health care professional immediately. Finally, you
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“Dangerous Drugs” in the News
should check your blood pressure regularly, especially if you are using Zyban with a nicotine
patch.
The Serotonin Reuptake Inhibitor Antidepressants (SSRIs)
The SSRI antidepressants (such as Paxil, Prozac and others) are commonly used for anxiety
and depression as well as many other conditions. They have been promoted for conditions such
as weight loss, incontinence, alcoholism, cocaine dependence, migraines, pain, fibromyalgia,
irritable bowel syndrome, compulsive shopping and many other uses. These are considered “offlabel” uses or uses for which the medicine has not been officially approved by Health Canada.
“Off-label” prescribing is common and can be beneficial for many people. However, recently,
concern that use of these antidepressants can lead to an increased risk of aggression, violence,
and suicide has surfaced. This is even more concerning because the use of these antidepressants
has skyrocketed, particularly for “off-label” uses.
If you or a family member are taking an SSRI antidepressant, you should watch for any of the
following symptoms, and if they occur, report them immediately to your health care provider:
thoughts of suicide or suicide attempt; new or worsening depression; or anxiety; feeling agitated,
irritable or panicky; acting aggressively, violently or in a dangerous manner; being extremely
hyperactive in actions and talking; or any other unusual behavior.
Bextra (valdecoxib) and Celebrex (celecoxib)
Bextra and Celebrex (celecoxib) are used mainly for arthritis pain, menstrual pain, or other
pain. Many experts are concerned that Bextra and Celebrex can lead to an increased chance of
heart problems or stroke. Bextra and Celebrex are similar to Vioxx, which was just taken off the
market due to these types of problems. As of April 2005, Bextra is no longer available because
of these problems as well as the severe rash it can cause. For more information on Bextra’s
withdrawal go to:
http://www.hc-sc.gc.ca/english/protection/warnings/2005/2005_17.html.
The chance of a problem in any one patient is very low, but since the problem seems to be
related to cardiovascular disease, it makes sense to try to avoid Celebrex in patients who have
heart problems.
Patients who have heart trouble and are taking Celebrex should talk with their health care
professional.
People who are not likely to benefit from Celebrex may be better off on a regular NSAID
(such as Motrin or Advil or a store’s brand product) or acetaminophen (such as Tylenol or a
store’s brand product). Patients should discuss this with their pharmacist and/or physician.
For more information on Celebrex go to:
http://www.hc-sc.gc.ca/english/protection/warnings/2004/2004_67_e.html
http://www.pfizer.ca/english/newsroom/press%20releases/default.asp?s=1&releaseID=149
Just recently, the FDA issued a patient advisory statement on naproxen (Aleve, Naprosyn)
which can be bought over-the-counter in the U.S. Preliminary information from an Alzheimer’s
disease study showed some evidence of increased risk of cardiovascular events in patients taking
naproxen. The FDA advises that patients should not exceed the recommended dose of 220 mg
twice daily for longer than ten days unless a physician directs otherwise.
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“Dangerous Drugs” in the News
Remember
Every medicine has side effects. Your pharmacist and/or physician know the possible side
effects of drugs and can carefully weigh the benefit of medicines against their risks. Your health
care professional will review possible side effects with you and give you information about how
to reduce these risks. Be sure to ask any questions you have when a drug is prescribed or
dispensed and while you are taking it. Always follow the medication instructions that your
health care professional gives you. Never share medications since this is a very dangerous
practice. Be sure to get your medicines from a trusted pharmacist.
If you have any concerns, please feel free to discuss them with your health care professional
who gave you this handout.
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Information for Patients Taking Celebrex or Naproxen
Celebrex (celecoxib) and naproxen are used mainly for pain such as arthritis pain. Many patients
also use them for menstrual pain. Many experts are now concerned that Celebrex and naproxen
can lead to an increased chance of heart problems or stroke. Celebrex is similar to Vioxx and
Bextra which were taken off the market due to these types of problems. Naproxen is a regular
painkiller like Motrin or Advil.
The chance of a problem in any one patient is very low. It is important to remember that many
millions of people have used these medicines and many are still using them. Researchers
continuously conduct studies to learn more about the drugs. Recently, researchers were studying
to see if Celebrex was useful to prevent colon cancer. During the course of the study researchers
noticed that there was an increase in heart problems in the people who were taking Celebrex.
These studies usually run for years and involve many patients. In this case it requires statistical
calculations to determine that there was an increase in heart problems in the patients taking
Celebrex. Just recently, the FDA issued a patient advisory statement on naproxen (Aleve,
Naprosyn) which can be bought over-the-counter in the U.S. Preliminary information from an
Alzheimer’s disease study showed some evidence of increased risk of cardiovascular events in
patients taking naproxen. Any individual patient who has taken Celebrex or naproxen should not
become overly concerned.
Since the problem seems to be related to cardiovascular disease, it makes sense to try to avoid
Celebrex in patients who have heart problems. Patients who have heart trouble and are taking
Celebrex or naproxen should talk with their health care professional to see if some other therapy
might be better for them.
Bextra, Celebrex, and Vioxx are called COX-2 inhibitor drugs. These drugs are actually in the
same family of drugs that are called nonsteroidal anti-inflammatory drugs (NSAIDs). One of the
problems with some nonsteroidal anti-inflammatory drugs (NSAIDs) is that they can sometimes
lead to bleeding in the stomach. It was thought that the COX-2 drugs such as Bextra, Celebrex,
and Vioxx would not lead to as much bleeding in the stomach as the other nonsteroidal antiinflammatory drugs (NSAIDs). So patients who had ulcers or other chance of bleeding in the
stomach or intestinal track often got a drug like Bextra, Celebrex, or Vioxx instead of the regular
nonsteroidal anti-inflammatory drugs (NSAIDs). Pharmaceutical firms encouraged physicians to
use these COX-2 drugs for many people. Many people might be better off on a regular NSAID
(such as Motrin, Advil, or a store’s brand product), or acetaminophen (such as Tylenol or a store’s
brand product). Patients should not exceed the recommended dose or duration printed on any
over-the-counter medicine bottle unless a physician directs otherwise. Patients should discuss
this with their pharmacist and/or physician.
There was a separate concern related to Bextra. It could cause severe rash, which in some cases
was life-threatening. This reaction was unpredictable, and could happen after short or long
periods of use. In April 2005, Health Canada asked Pfizer Canada, the manufacturer of Bextra, to
voluntarily withdraw Bextra from the market.
For more information go to:
http://www.hc-sc.gc.ca/english/protection/warnings/2004/2004_67_e.html
http://www.pfizer.ca/english/newsroom/press%20releases/default.asp?s=1&releaseID=149
http://www.hc-sc.gc.ca/english/protection/warnings/2005/2005_17.html
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Safety Information Regarding Selective COX-2 Inhibitor NSAIDs: Vioxx,
(Rofecoxib), Celebrex (Celecoxib), Bextra (Valdecoxib), Mobicox
(Meloxicam) and Generic Forms of Meloxicam
The following excerpts are reprinted from the
December 22, 2004 Health Canada Advisory on safety
information regarding selective COX-2 Inhibitors.
http://www.hcsc.gc.ca/english/protection/warnings/2004/2004_69_e.
html

COX-2 inhibitor NSAIDs (Celebrex, Bextra,
Mobicox, and all generic forms of meloxicam).
Patients should discuss the benefits and risks
of treatment options with their physician, in light
of the following information.

Health Canada wishes to inform Canadians of
safety concerns regarding the group of drugs
known as selective COX-2 inhibitor NSAIDs
(non-steroidal anti-inflammatories).
These
include Vioxx (rofecoxib), which has been
withdrawn from the market, Celebrex (celecoxib),
Bextra (valdecoxib), and Mobicox (meloxicam),
which are used in the treatment of symptoms of
rheumatoid arthritis, osteoarthritis and primary
dysmenorrhea (menstrual pain).
Accumulating evidence indicates that the use
of selective COX-2 inhibitor NSAIDs, in certain
individuals, is associated with an increased risk of
heart attack or stroke when compared to placebo.
The risk appears to increase with the total daily
dose and the length of the treatment. However,
given the available data, it is not possible to
identify which patients would present a higher
risk of heart attack and stroke.
Health Canada has requested additional safety
information from the manufacturers of Celebrex,
Bextra, Mobicox and generic forms of meloxicam,
and will continue to review the safety profile of
these drugs in order to fully consider what is
presently known about the risks and benefits of
these drugs when used according to their
labelling.
Until further information from long-term
clinical trials becomes available, one should
consider that there is a strong possibility of an
increased risk of cardiovascular events, including
heart attack and stroke, when using selective

Vioxx (rofecoxib)
Vioxx was withdrawn on September 30, 2004,
based on new safety information from a threeyear, randomized double-blind clinical trial, called
APPROVe, showing a possible increased risk of
cardiovascular events.
The APPROVe
(Adenomatous Polyp Prevention on VIOXX)
clinical trial was designed to assess the
effectiveness of 25 mg Vioxx in preventing the
recurrence of colon polyps (abnormal tissue
growth, which may or may not be cancerous). In
the APPROVe trial, Vioxx was compared to a
placebo (sugar pill). Merck & Co withdrew Vioxx
from the worldwide market after the study
indicated an increased risk of serious
cardiovascular events, such as heart attacks and
strokes, after 18 months of continuous treatment.

Bextra (valdecoxib)
On December 10, 2004, Pfizer Inc. released
new information about cardiovascular risks
associated with Bextra. In a study conducted by
Pfizer, which included over 1,500 patients treated
for acute pain after coronary artery bypass
grafting (CABG), an increased risk of
cardiovascular events was observed in patients
treated with Bextra compared to placebo. These
cardiovascular events included myocardial
infarction (heart attack), cerebrovascular accident
(stroke), deep vein thrombosis (blood clots in the
leg), and pulmonary embolism (blood clot in the
lung). The risk of these effects was observed to
be greater with the intravenous form of the drug
More. . .
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(approximately two percent of patients had such
an adverse event), in comparison with the oral
form of the drug (approximately 1 percent of
patients), immediately following CABG surgery.
About 0.5 percent of patients taking the placebo
had an adverse cardiovascular event.

Celebrex (celecoxib)
On December 17, 2004, the National Cancer
Institute (NCI) in the United States announced
that it had stopped a three-year Celebrex study
called Adenoma Prevention with Celecoxib
(APC) due to an interim analysis showing a
statistically significant increase in the risk of heart
attack, stroke and cardiovascular death. Health
Canada has withdrawn market authorization for
the use of Celebrex for the prevention of
recurrence of Familial Adenomatous Polyposis,
which is predictive of colorectal cancer. Celebrex
should not be taken for the prevention of
recurrence of Familial Adenomatous Polyposis
and patients should discuss alternative therapeutic
options with their doctors.

Background on Selective COX-2 Inhibitor
NSAIDs
Selective COX-2 inhibitor NSAIDs were first
authorized for sale in Canada in 1999 based on
data showing a better gastrointestinal safety
profile than traditional (non-selective) NSAIDs

(for example, ibuprofen). There was a need for
new therapies because of the well-documented
frequent and severe gastrointestinal adverse
events (for example ulcers and gastric
haemorrhages) associated with the use of
traditional (non-selective) NSAIDs.
Also, a
significant number of patients could not tolerate
traditional (non-selective) NSAIDs because of
stomach upset.
It should be noted that alternative therapies to
selective COX-2 inhibitor NSAIDs also present
risks. Therefore, patients should discuss with
their physician all benefits and risks of selective
COX-2 inhibitor NSAIDs versus alternative
therapies, in order to determine the most
appropriate treatment in their individual case.

Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.

Continue to the next page for more professional information.
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Professional Information

“Dangerous Medications” - Preventing Serious Side Effects
Lead authors: Joseph A. Woelfel, Ph.D., FASCP, R.Ph., Assistant Editor
and Neeta Bahal O’Mara, Pharm.D., BCPS

Background
The recent removal of the painkiller, Vioxx
(rofecoxib) because of the possibility that it
causes heart attacks and strokes has led people to
question the safety of other medicines.1
On November 18, 2004, Dr. David Graham
testified before the U.S. Senate Committee on
Finance. Dr. Graham is the Associate Director for
Safety, Office of Drug Safety for the Food and
Drug Administration. In his presentation made at
the hearing on FDA, “Merck and Vioxx: Putting
Patient Safety First,” he identified five FDAapproved “dangerous drugs.” These include the
diet drug Meridia (sibutramine), the cholesterol
drug Crestor (rosuvastatin), the acne medication
Accutane (isotretinoin), the anti-inflammatory
drug Bextra, and the asthma medicine Serevent
(salmeterol).1 The risks associated with these
FDA-approved products that Dr. Graham
identified are well known. The larger concern is
that there may be system problems in checks and
balances for rapid drug approval versus safety
assurance.
Similarly, a recent report in the Toronto Star
newspaper highlighted medicines or medicine
groups that the writers felt were unsafe.2-6 The
risks associated with these products are wellknown and can often be minimized.

Minimizing “Dangerous Drug” Effects
Appropriate
prescribing,
dispensing,
administration, and monitoring of medication use
are essential for assurance of patient safety.
The HMG-CoA reductase inhibitors or
“statins” such as Lipitor (atorvastatin), Zocor
(simvastatin), or Crestor (rosuvastatin) can cause
rhabdomyolysis or hepatotoxicity. Patients should
report any muscle pain or weakness as well as any
signs of liver problems such as yellow skin or
sclera. Liver function tests should be routinely
monitored and the medication should be stopped

if the AST or ALT increases to greater than three
times the upper limit of normal.
The consumer advocacy group, Public Citizen,
has specifically admonished Crestor for causing
kidney damage and rhabdomyolysis. In general,
the risk of rhabdomyolysis is higher with higher
doses. In fact, Health Canada recently released
important safety information warning about
concerns with the 40 mg dose.7 The 40 mg
dosage must not be used in patients who have preexisting medical conditions or other factors which
put them at increased risk for rhabdomyolysis.
This includes Asian ethnicity, serious kidney or
liver problems, concomitant use with fibrates or
niacin,
hypothyroidism,
situations
where
increased Crestor blood levels may occur,
personal or family history of hereditary muscle
problems, previous history of statin-induced
muscle toxicity, and alcohol abuse. Patients
should be maintained on the lowest dose meeting
their therapeutic goal. For Asian patients and all
patients with severe renal impairment (CLcr <30
mL/min/1.73m2), a starting dosage of 5 mg once
daily is recommended. The 5 mg dose should be
considered for all patients requiring less
aggressive LDL-C reductions and those with
predisposing factors for myopathy.7,8
Meridia (sibutramine) for weight loss can
increase blood pressure and also heart rate. Obese
patients may already present with underlying heart
and vascular problems so caution in prescribing is
essential. Meridia is under scrutiny from Public
Citizen because of these potentially dangerous
side effects.9 Tell patients to check their blood
pressure and heart rate regularly, and report any
abnormal increases. Emphasize healthy lifestyle
changes.10
Xenical (orlistat) decreases the amount of fat
that is absorbed into the body. But blocking
absorption of fat can result in loose, oily stools
and diarrhea. Other side effects include stomach
More. . .
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cramping, pancreatitis, and vitamin deficiencies.
Make sure patients who take Xenical divide their
daily fat intake evenly over their three main meals
and take a multivitamin that contains vitamins D,
E, K, and beta-carotene. This multivitamin
should be taken at least two hours before or after
taking Xenical.11
Zyban (bupropion) is a non-nicotine medicine
approved for smoking cessation. Zyban reduces
the nicotine withdrawal symptoms and the urge to
smoke.
It is more effective when patients
combine it with a patient support program.
However, there is concern about a number of
side effects.5 Rarely, patients who are taking
Zyban have had heart attacks. But, smokers are at
high risk for cardiovascular disease and it is
difficult to establish causality between Zyban and
the heart attack. Other side effects include
thoughts of suicide or suicide attempts and
seizures.
Because of the possibility of seizures, patients
who have a history of a seizure disorder, an eating
disorder such as bulimia or anorexia nervosa, or
are discontinuing the use of alcohol or sedatives
should not receive Zyban, since these conditions
may increase the chance of seizures while taking
Zyban. Also, when used for smoking cessation,
the dose should not exceed 150 mg twice a day.
As with the serotonin reuptake inhibitor
antidepressants, patients and their families should
watch for depression; thoughts of suicide; or
feelings of anxiety, irritability, hostility, severe
restlessness, mania, or insomnia. Finally, blood
pressure should be closely monitored, especially if
Zyban is being used concomitantly with a nicotine
patch.12
Serotonin reuptake inhibitors (SSRIs)
antidepressants [such as Paxil (paroxetine),
Prozac (fluoxetine) and others] are approved for
use for anxiety and depression. However, there is
a growing list of use in off-label populations such
as children and adolescents, and for a variety of
off-label uses such as weight loss, incontinence,
alcoholism, cocaine dependence, migraines, pain,
fibromyalgia,
irritable
bowel
syndrome,
compulsive shopping, and many others. With the
increasing use in a broader range of patients,
concern that use of these antidepressants can lead
to an increased risk of aggression, violence, and
suicide has surfaced.

Patients, and families of patients taking an
SSRI antidepressant, should watch for any of the
following symptoms and if they occur, report
them immediately: thoughts of suicide or suicide
attempt; new or worsening depression or anxiety;
agitation or irritability; acting aggressively,
violently or in a dangerous manner, mania in
actions and talking; or any other unusual
behavior.13
Bextra (valdecoxib) had new warnings added
this December 2004. Serious skin rashes such as
toxic epidermal necrolysis, Stevens-Johnson
syndrome, and erythema multiforme can occur
anytime but usually occur within the first two
weeks of therapy. Advise patients to watch for
rashes, lesions, or unusual swelling and
discontinue Bextra at the first sign of these. They
should immediately call their health care
professional when this occurs. Additionally,
Bextra is contraindicated for the treatment of postcoronary bypass surgery (CABG) pain. In this
group of patients, Bextra is contraindicated due to
cardiovascular thromboembolic adverse events. A
new bolded warning is being added to the label.
Caution should be used when using Bextra in
patients with ischaemic heart disease or other
factors that may predispose to cardiovascular
events such as congestive heart failure, unstable
angina, uncontrolled hypertension, myocardial
infarction, transient ischaemic attacks, and
stroke.14 On April 7, 2005 Health Canada
requested that Pfizer withdraw Bextra from the
market.17 For more information on Bextra’s
withdrawal
go
to:
http://www.hcsc.gc.ca/english/protection/warnings/2005/2005
_17.html.
Celebrex (celecoxib). On December 17, 2004,
Pfizer issued a news release that in the Adenoma
Prevention with Celecoxib (APC) trial, patients
taking 400 mg and 800 mg of Celebrex daily had
an approximately 2.5 fold increase in major fatal
or non-fatal cardiovascular events compared with
placebo. As a result of this finding, the APC
colon cancer prevention trial was stopped.
Though higher-than-recommended doses were
used in the trial, these findings further raise safety
concerns.15 For more information go to:
http://www.hcsc.gc.ca/english/protection/warning
s/2004/2004_67_e.html
http://www.pfizer.ca/english/newsroom/press%20
releases/default.asp?s=1&releaseID=149.
On
More. . .
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April 7, 2005 Health Canada announced new
restrictions concerning the use of Celebrex.17
These are:
• Patients who have had a heart attack or
stroke, experienced serious chest pain
related to heart disease, or who have had
serious diseases of the heart such as
congestive heart failure, should NOT use
this medication
• Patients who have significant risk factors
for heart attack or stroke should be aware
that using this drug may increase this risk
• This medication should be prescribed and
used at the lowest possible dose, and for
the shortest, necessary period of time
• Selective COX-2 inhibitor NSAIDs should
only be used to treat the pain and
inflammation of arthritis, and certain types
of acute pain
On December 20, 2004, the FDA issued a
patient advisory statement on naproxen (Aleve,
Naprosyn) which can be bought over-the-counter
in the U.S. Preliminary information from an
Alzheimer’s disease study showed some evidence
of increased risk of cardiovascular events in
patients taking naproxen. The FDA advises that
patients should not exceed the recommended dose
of 220 mg twice daily for longer than ten days
unless a physician directs otherwise.16
Active involvement by patients in managing
their medication with their health care
professionals will minimize the dangerous effects
of these drugs.
Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.
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